AVROBIO, Inc. – NASDAQ:AVRO
Founder-led company
AVROBIO stock price today
$1.45
+0.05
+3.57%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
AVROBIO stock price monthly change
+1.45%
month
AVROBIO stock price quarterly change
+7.69%
quarter
AVROBIO stock price yearly change
+32.08%
year
AVROBIO key metrics
Market Cap | 5.23M |
Enterprise value | N/A |
P/E | -0.39 |
EV/Sales | N/A |
EV/EBITDA | 0.30 |
Price/Sales | N/A |
Price/Book | 0.55 |
PEG ratio | N/A |
EPS | 0.70 |
Revenue | N/A |
EBITDA | -51.96M |
Income | 30.30M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAVROBIO stock price history
AVROBIO stock forecast
AVROBIO financial statements
| Jun 2023 | 0 | 67.47M | |
|---|---|---|---|
| Sep 2023 | 0 | -21.57M | |
| Dec 2023 | 3.59M | -8.78M | -244.16% |
| Mar 2024 | 0 | -6.80M |
| Mar 2024 | 0 | -6.80M | |
|---|---|---|---|
| Sep 2025 | 0 | -5.35M | |
| Oct 2025 | 0 | -5.37M | |
| Dec 2025 | 0 | -5.37M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-09 | -0.23 | -0.44 |
|---|
| Jun 2023 | 133835000 | 11.79M | 8.82% |
|---|---|---|---|
| Sep 2023 | 110522000 | 7.66M | 6.93% |
| Dec 2023 | 101093000 | 6.35M | 6.29% |
| Mar 2024 | 92348000 | 3.50M | 3.8% |
| Jun 2023 | -14.65M | 83.73M | -16.32M |
|---|---|---|---|
| Sep 2023 | -20.22M | 1.19M | 178K |
| Dec 2023 | -8.03M | 150K | 59K |
| Mar 2024 | -7.56M | 0 | 30K |
AVROBIO alternative data
| Aug 2023 | 78 |
|---|---|
| Sep 2023 | 78 |
| Oct 2023 | 78 |
| Nov 2023 | 78 |
| Dec 2023 | 78 |
| Jan 2024 | 78 |
| Feb 2024 | 78 |
| Mar 2024 | 13 |
| Apr 2024 | 13 |
| May 2024 | 13 |
| Jun 2024 | 13 |
| Jul 2024 | 13 |
AVROBIO other data
68.47%
-11.88%
of AVRO is owned by hedge funds
75
-15
29.34M
-5.70M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 766635 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | LEONARD BRADEN MICHAEL 10 percent owner | Common Stock | 296,882 | $1.3 | $385,947 | ||
Purchase | LEONARD BRADEN MICHAEL 10 percent owner | Common Stock | 216,053 | $1.26 | $272,227 | ||
Purchase | LEONARD BRADEN MICHAEL 10 percent owner | Common Stock | 253,700 | $1.24 | $313,320 | ||
Option | GOLIPOUR AZADEH officer: Chief Technology Officer | Restricted Stock Unit | 37,334 | N/A | N/A | ||
Option | GOLIPOUR AZADEH officer: Chief Technology Officer | Common Stock | 37,334 | N/A | N/A | ||
Option | RIDHA ESSRA officer: Chief Medical Officer | Restricted Stock Unit | 32,834 | N/A | N/A | ||
Option | RIDHA ESSRA officer: Chief Medical Officer | Common Stock | 32,834 | N/A | N/A | ||
Option | OSTROWSKI ERIK officer: Interim CEO, President.. | Restricted Stock Unit | 40,084 | N/A | N/A | ||
Option | OSTROWSKI ERIK officer: Interim CEO, President.. | Common Stock | 40,084 | N/A | N/A | ||
Option | AVRUCH STEVEN officer: Chief Le.. | Restricted Stock Unit | 32,834 | N/A | N/A |
| Patent |
|---|
Application Filling date: 31 Jan 2020 Issue date: 5 May 2022 |
Application Filling date: 31 Jan 2020 Issue date: 5 May 2022 |
Application Filling date: 31 Jan 2020 Issue date: 14 Apr 2022 |
Application Filling date: 8 Mar 2019 Issue date: 7 Jan 2021 |
| Insider | Compensation |
|---|---|
Mr. Geoff MacKay BSc (1966) Co- Founder, Pres, Chief Executive Officer & Director | $811,230 |
Mr. Erik Ostrowski M.B.A. (1973) Chief Financial Officer & Treasurer | $597,080 |
| Mr. Steven N. Avruch J.D. (1961) Chief Legal Officer & Sec. | $506,680 |
-
What's the price of AVROBIO stock today?
One share of AVROBIO stock can currently be purchased for approximately $1.45.
-
When is AVROBIO's next earnings date?
Unfortunately, AVROBIO's (AVRO) next earnings date is currently unknown.
-
Does AVROBIO pay dividends?
No, AVROBIO does not pay dividends.
-
How much money does AVROBIO make?
AVROBIO has a market capitalization of 5.23M. AVROBIO earned 12.16M US dollars in net income (profit) last year or -$0.44 on an earnings per share basis.
-
What is AVROBIO's stock symbol?
AVROBIO, Inc. is traded on the NASDAQ under the ticker symbol "AVRO".
-
What is AVROBIO's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of AVROBIO?
Shares of AVROBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AVROBIO's key executives?
AVROBIO's management team includes the following people:
- Mr. Geoff MacKay BSc Co- Founder, Pres, Chief Executive Officer & Director(age: 59, pay: $811,230)
- Mr. Erik Ostrowski M.B.A. Chief Financial Officer & Treasurer(age: 52, pay: $597,080)
- Mr. Steven N. Avruch J.D. Chief Legal Officer & Sec.(age: 64, pay: $506,680)
-
Is AVROBIO founder-led company?
Yes, AVROBIO is a company led by its founder Mr. Geoff MacKay BSc.
-
How many employees does AVROBIO have?
As Jul 2024, AVROBIO employs 13 workers.
-
When AVROBIO went public?
AVROBIO, Inc. is publicly traded company for more then 7 years since IPO on 21 Jun 2018.
-
What is AVROBIO's official website?
The official website for AVROBIO is avrobio.com.
-
Where are AVROBIO's headquarters?
AVROBIO is headquartered at Building 300, Cambridge, MA.
-
How can i contact AVROBIO?
AVROBIO's mailing address is Building 300, Cambridge, MA and company can be reached via phone at +61 79148420.
AVROBIO company profile:
AVROBIO, Inc.
avrobio.comExchange:
NASDAQ
Full time employees:
13
Industry:
Biotechnology
Sector:
Healthcare
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Building 300
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001681087
ISIN: US05455M1009
CUSIP: 05455M100
